Lasofoxifene

Lasofoxifene (INN) (proposed tradename Fablyn) is a selective estrogen receptor modulator (SERM) which is under development for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.

In September 2005, Pfizer Inc. received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (Oporia®), a selective estrogen receptor modulator for the prevention of osteoporosis.

On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is now to be marketed under the tradename Fablyn.